Inhibition of lymphocyte capping and transformation by propranolol and related compounds

The immunomodulatory effects of antihypertensive therapy: A review

Hypertension remains the leading preventable risk factor for stroke and coronary artery disease, significantly contributing to all-cause global mortality and predisposing patients to renal and heart failure, as well as peripheral vascular disease. Due to the widespread usage of antihypertensive drugs, global mean blood pressure has remained unchanged or even slightly decreased over the past four decades. However, considering the broad spectrum of mechanisms involved in the action of antihypertensive drugs and the prevalence of their target receptors on immune cells, possible immunomodulatory effects which may exert beneficial effects of lowering blood pressure but also potentially alter immune function should be considered. In this review, we attempt to assess the consequences to immune system function of administering the five most commonly prescribed groups of antihypertensive drugs and to explain the mechanisms behind those interactions. Finally, we show potential gaps in our understanding of the effects of antihypertensive drugs on patient health. With regard to the widespread use of these drugs in the adult population worldwide, the discussed results may be of vital importance to evidence-based decision-making in daily clinical practice.

Evidence for a dual effect of acebutolol, a beta blocker, on the mouse humoral immune response

Acebutolol induces transient polyclonal B cell activation in C57B1/6 mice but down-modulates the spontaneous polyclonal activation of NZBxNZW lupus mice. The immunomodulatory effects of this beta-blocker were studied in C57l/6 mice injected with LPS or immunized with sheep red blood cells. The effect of acebutolol on the polyclonal activation of lymphocytes induced by LPS was also investigated in heterozygous and nu/nu C57BL/6 mice. Finally, the direct effect of acebutolol on spleen cells was studied in vitro. Acebutolol treatment for 15 days (50mg/kg/day) inhibited the polyclonal activation of lymphocytes induced by LPS in C57BL/6 and in C57BI/6 nu/nu mice, but increased the humoral response to sheep red blood cells in C57Bl/6 mice. Moreover, spleen cells from C57Bl/6 mice treated for 15 days with acebutolol showed an increased number of CD5+ and CD4+ lymphocytes, as well as an increased reactivity to concanavalin A but not to LPS. In vitro, acebutolol at 10(-5)-10(-7) M induced an increased reactivity of spleen cells from naive mice to concanavalin A, whereas it did not affect the B cell responsiveness to LPS. These results indicate that acebutolol modulates both T-cells and non T-cells in the immune system.

Noradrenaline receptors participate in the regulation of GABAergic inhibition in area CA1 of the rat hippocampus

1. Standard intracellular recordings from CA1 pyramidal neurones in in vitro hippocampal slices have been used to investigate the effects of excitatory amino acid antagonists and adrenergic agents on evoked synaptic potentials. 2. Ortho- and antidromic stimulation were conducted with remotely placed electrodes in order to minimize the possibility of stimulating the interneurones directly. In addition to the excitatory postsynaptic potential (EPSP), orthodromic stimulation evoked an inhibitory sequence consisting of a fast and slow inhibitory postsynaptic potential (IPSP). The slow-IPSP was blocked by intracellular injection of QX 314. Antidromic stimulation evoked a relatively pure fast-IPSP. 3. In seven neurones the differential effects of glutamatergic receptor blockers on the fast-IPSP were investigated. The N-methyl-D-aspartate (NMDA) receptor blocker, DL-2-amino-5-phosphonovaleric acid (APV) was added after the full effect of the non-NMDA receptor blocker, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) had been achieved. In three neurones, APV had no additional blocking effect, while in the remaining four neurones, both the ortho- and antidromically evoked IPSPs were reduced by 20-50%. This suggests that NMDA receptors participate in the activation of some GABAergic interneurones, which was further confirmed by showing that the IPSP was enhanced by Mg(2+)-free medium. 4. In the presence of CNQX (10 microM) and APV (50 microM) together, the ortho- and antidromically evoked fast-IPSPs were greatly reduced. A small 'residual' IPSP remained which was best studied by depolarizing the neurone to around -50 mV. With maximum stimulation, this amounted to 26.3 +/- 15.4% (mean +/- S.E.M., n = 15) of the control IPSP evoked by orthodromic stimulation and 41 +/- 14.6% of the control IPSP evoked by antidromic stimulation. The following statements apply equally to the ortho- and antidromically activated residual IPSPs. 5. The residual IPSP was completely blocked by low concentrations of bicuculline, indicating that it is mediated by GABAA receptors. When compared with a control IPSP of similar amplitude, the residual IPSP was found to have a faster rise time and time-to-peak, but a similar decay time. 6. Neither the muscarinic cholinergic antagonist, atropine nor the presynaptic glutamate agonist, L-2-amino-4-phosphonobutyric acid (L-APB) had any effect on the residual IPSP. 7. The residual IPSP was completely blocked by the adrenergic beta-receptor antagonist, L-propranolol (50-100 microM).(ABSTRACT TRUNCATED AT 400 WORDS)

Beta blockers may induce in C57BL/6 mice a polyclonal activation of lymphocytes which is not mediated by beta adrenergic receptors

The in vivo immune effects of nine beta (beta)-blockers are studied in C5B1/6 mice after 7 days of treatment. Humoral and cellular studies indicate that several beta-blocking agents, particularly pindolol and acebutolol, may induce a polyclonal activation of lymphocytes. It may involve all the classes and subclasses of immunoglobulins with a preferential effect on IgA and IgG2a. Further investigations, conducted using the laevorotatory and dextrorotatory forms of pindolol indicate that this immune effect is not mediated by specific beta-adrenergic receptors.

Transglutaminase may mediate certain physiological effects of endogenous amines and of amine-containing therapeutical agents

Transglutaminase mediation of the effects of certain primary amines and alcohols may be important in receptor coupling to physiological responses. Many of the therapeutic and toxic side effects of drugs also may be related to their covalent linkage of glutamine residues of key regulatory proteins through the catalytic action of transglutaminase. This paper suggests that important therapeutic agents such as digoxin, tetracycline, adriamycin, and actinomycin D may have some effects related to transglutaminase action.

Inhibition of human lymphocyte transformation by two aryloxyalkylamidines

The incorporation of [3H]thymidine into human lymphocytes stimulated by phytohaemagglutinin (PHA) was inhibited by anilino-N-2-m-chlorophenoxypropylacetamidine (501C) and xylamidine. These amidines antagonize 5-HT, but 5-HT did not alter [3H]thymidine incorporation. 501C inhibited PHA-induced lymphocyte transformation as observed by [3H]thymidine incorporation, [3H]uridine incorporation, [3H]leucine incorporation, DNA content, potassium content, and histological examination. 501C also inhibited increased [3H]thymidine incorporation in human mixed lymphocyte cultures. The IC50 of 501C for inhibition of these processes lay between 4 and 8 microM. When added late in culture (after 6-8 h) 501C was less effective. Possible mechanisms by which 501C inhibits transformation are discussed.